NUVA : Summary for NuVasive, Inc. - Yahoo Finance

U.S. Markets closed

NuVasive, Inc. (NUVA)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
75.32+0.03 (+0.04%)
At close: 4:00PM EDT

75.32 0.00 (0.00%)
After hours: 4:35PM EDT

People also watch
WMGIOFIXPODDNXTMMASI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close75.29
Open75.30
Bid70.00 x 100
Ask80.00 x 200
Day's Range74.92 - 75.53
52 Week Range47.73 - 76.31
Volume243,656
Avg. Volume523,272
Market Cap3.81B
Beta1.11
PE Ratio (TTM)109.16
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire9 hours ago

    NuVasive Receives First-Ever FDA Clearance For Cervical Interbody Implant System Used In More Than Two Levels

    SAN DIEGO, March 29, 2017 /PRNewswire/ -- NuVasive, Inc. (NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the CoRoent® Small Interbody™ System indicated for intervertebral body fusion at multiple contiguous levels in the cervical spine. This marks the first U.S. clearance for a cervical cage to be used at up to four contiguous levels. "This FDA 510(k) clearance is another key milestone for NuVasive as we continue to deliver new innovation to the spine market.

  • PR Newswire9 days ago

    New Evidence-Based Recommendation Released From NICE (U.K.) For Lateral Interbody Fusion

    SAN DIEGO, March 20, 2017 /PRNewswire/ -- NuVasive, Inc. (NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced updated guidance from the National Industry for Clinical Excellence (NICE) in the U.K. for lateral interbody fusion in the lumbar spine. NICE stated the evidence on efficacy for lateral interbody fusion is adequate in quality and quantity and the procedure may be used provided that standard arrangements are in place for clinical governance, consent and audit. The majority of the evidence submitted to and reviewed by the panel was peer-reviewed journal articles describing the now 14-year experience with and outcomes following the Company's eXtreme Lateral Interbody Fusion (XLIF®) procedure, the leading global lateral approach spine surgical technique.

  • Why Is NuVasive (NUVA) Up 3.1% Since the Last Earnings Report?
    Zacks14 days ago

    Why Is NuVasive (NUVA) Up 3.1% Since the Last Earnings Report?

    NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.